在一项关键研究中,新的COPD药物Itepekimab在前吸烟者中将严重的肺炎率增加了27%。 New COPD drug Itepekimab cuts severe lung flare-ups by 27% in former smokers in one key study.

在两项第三期研究中,Itepekimab是一种新的COPD治疗方法,在前吸烟者中显著减少了严重的肺炎发作,与安慰剂相比,该药物减少了27%. Itepekimab, a new treatment for COPD, showed a significant reduction in severe lung flare-ups in former smokers in one of two phase 3 studies, lowering incidents by 27% compared to a placebo. 然而,第二项研究并没有实现其主要目标。 However, the second study did not meet its primary goal. 该药物普遍开销良好,开发该药物的公司Sanofi和Regeneron正在审查数据,以便决定下一步措施。 The drug was generally well-tolerated, and the companies developing it, Sanofi and Regeneron, are reviewing the data to decide the next steps.